US 12,145,945 B2
Compounds, compositions, and therapeutic uses thereof
Andrea Guerrero Corella, Abingdon (GB); Stuart Robert Flanagan, Abingdon (GB); Jonathan Hollick, Hamburg (DE); Julien Gilbert Jacques Malassis, Toulouse (FR); Matthew Raymond Smith, Abingdon (GB); Ian Andrew Yule, Abingdon (GB); and Jonathan Mark Bentley, Abingdon (GB)
Assigned to Breakpoint Therapeutics GmbH, Hamburg (DE)
Filed by Breakpoint Therapeutics GmbH, Hamburg (DE)
Filed on Mar. 8, 2024, as Appl. No. 18/600,352.
Claims priority of application No. 2303582 (GB), filed on Mar. 10, 2023; application No. 2308738 (GB), filed on Jun. 12, 2023; and application No. 2312354 (GB), filed on Aug. 11, 2023.
Prior Publication US 2024/0327430 A1, Oct. 3, 2024
Int. Cl. C07D 513/04 (2006.01); A61K 31/4545 (2006.01)
CPC C07D 513/04 (2013.01) [A61K 31/4545 (2013.01)] 4 Claims
 
1. A compound having the structure shown below:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.